Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 1;60(5):755-759.
doi: 10.2169/internalmedicine.5677-20. Epub 2020 Oct 7.

Effective Use of Keishibukuryogan in Subcutaneous Hematoma after Implantable Cardiac Device Surgery in Two Cases

Jun Kumanomido  1 , Masatsugu Ohe  1 , Ryo Shibata  1 , Yuichi Hattori  1 , Yuta Ishizaki  1 , Shogo Ito  1 , Yume Nohara  1 , Jinya Takahashi  1 , Kensuke Hori  1 , Aya Obuchi  1 , Masanori Ohtsuka  1 , Yoshihiro Fukumoto  1
Affiliations

Effective Use of Keishibukuryogan in Subcutaneous Hematoma after Implantable Cardiac Device Surgery in Two Cases

Jun Kumanomido et al. Intern Med. .

Abstract

Keishibukuryogan is a Kampo medicine that induces vasodilation and improves the blood flow velocity in subcutaneous blood vessels. We herein report two cases in which keishibukuryogan completely diminished subcutaneous hematoma after cardiac resynchronization therapy pacemaker implantation and defibrillator battery replacement within a month. Keishibukuryogan can be a good option for treating or preventing subcutaneous hematoma after surgical procedures for devices.

Keywords: Kampo; Kampo medicine; herbal medicine; implantable cardiac device surgery; keishibukuryogan; subcutaneous hematoma.

PubMed Disclaimer

Conflict of interest statement

The authors state that they have no Conflict of Interest (COI).

Figures

Figure 1.
Figure 1.
Chest X-ray (Case 1).
Figure 2.
Figure 2.
An electrocardiogram (Case 1).
Figure 3.
Figure 3.
Subcutaneous hematoma five days after the procedure (Case 1).
Figure 4.
Figure 4.
Subcutaneous hematoma three days after the administration of keishibukuryogan, eight days after the procedure (Case 1).
Figure 5.
Figure 5.
Subcutaneous hematoma 36 days after the administration of keishibukuryogan, 41 days after the procedure (Case 1).
Figure 6.
Figure 6.
Chest X-ray (Case 2).
Figure 7.
Figure 7.
An electrocardiogram (Case 2).
Figure 8.
Figure 8.
Subcutaneous hematoma four days after the procedure (Case 2).
Figure 9.
Figure 9.
Subcutaneous hematoma 37 days after the administration of keishibukuryogan, 41 days after the procedure (Case 2).
See this image and copyright information in PMC

References

    1. Sridhar AR, Yarlagadda V, Yeruva MR, et al. . Impact of haematoma after pacemaker and CRT device implantation on hospitalization costs, length of stay, and mortality: a population-based study. Europace 17: 1548-1554, 2015. - PubMed
    1. Turagam MK, Nagarajan DV, Bartus K, et al. . Use of a pocket compression device for the prevention and treatment of pocket hematoma after pacemaker and defibrillator implantation (STOP-HEMATOMA-I). J Interv Card Electrophysiol 49: 197-204, 2017. - PubMed
    1. Wiegand UK, Lejeune D, Bogushewaski F, et al. . Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. CHEST 126: 1177-1186, 2004. - PubMed
    1. Demir GG, Guier GB, Guler E, et al. . Pocket haematoma after cardiac electronic device implantation in patients receiving antiplatelet and anticoagulant treatment: a single-centre experience. Acta Cardiol 72: 47-52, 2017. - PubMed
    1. Tomita T, Hirayama A, Matsui H, Aoyagi K. Effect of keishibukuryogan, a japanese traditional kampo prescription, on improvement of microcirculation and oketsu and induction of endothelial nitric oxide: a live imaging study. Evid Based Completment Alternat Med. Forthcoming. - PMC - PubMed

MeSH terms